Efficacy of lithium in mania and maintenance therapy of bipolar disorder

Charles L. Bowden

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Lithium was introduced in 1949 as a treatment for mania, for which there is still the strongest evidence of its efficacy. It has consistently yielded better results in the treatment of mania than neuroleptics and carbamazepine and equivalent results to divalproex. Its efficacy in bipolar depression remains inadequately studied. Lithium also provides benefit in prophylaxis. However, the percentage of patients persistently benefited is low, because it has both low efficacy in many symptomatic and illness course presentations of the disorder and low tolerability. Converging evidence from clinical and animal studies indicates that a principal behavioral effect of lithium is reduction of motor activity. Lithium is increasingly used in combined treatment regimens, often thereby allowing lower, better tolerated dosing and complementary benefits from drugs with different profiles of action.

Original languageEnglish (US)
Pages (from-to)35-40
Number of pages6
JournalJournal of Clinical Psychiatry
Volume61
Issue numberSUPPL. 9
StatePublished - 2000

Fingerprint

Bipolar Disorder
Lithium
Carbamazepine
Valproic Acid
Therapeutics
Antipsychotic Agents
Motor Activity
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Efficacy of lithium in mania and maintenance therapy of bipolar disorder. / Bowden, Charles L.

In: Journal of Clinical Psychiatry, Vol. 61, No. SUPPL. 9, 2000, p. 35-40.

Research output: Contribution to journalArticle

Bowden, Charles L. / Efficacy of lithium in mania and maintenance therapy of bipolar disorder. In: Journal of Clinical Psychiatry. 2000 ; Vol. 61, No. SUPPL. 9. pp. 35-40.
@article{d2084b0ad51e40acb7d825f2ba057dcd,
title = "Efficacy of lithium in mania and maintenance therapy of bipolar disorder",
abstract = "Lithium was introduced in 1949 as a treatment for mania, for which there is still the strongest evidence of its efficacy. It has consistently yielded better results in the treatment of mania than neuroleptics and carbamazepine and equivalent results to divalproex. Its efficacy in bipolar depression remains inadequately studied. Lithium also provides benefit in prophylaxis. However, the percentage of patients persistently benefited is low, because it has both low efficacy in many symptomatic and illness course presentations of the disorder and low tolerability. Converging evidence from clinical and animal studies indicates that a principal behavioral effect of lithium is reduction of motor activity. Lithium is increasingly used in combined treatment regimens, often thereby allowing lower, better tolerated dosing and complementary benefits from drugs with different profiles of action.",
author = "Bowden, {Charles L.}",
year = "2000",
language = "English (US)",
volume = "61",
pages = "35--40",
journal = "The Journal of clinical psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 9",

}

TY - JOUR

T1 - Efficacy of lithium in mania and maintenance therapy of bipolar disorder

AU - Bowden, Charles L.

PY - 2000

Y1 - 2000

N2 - Lithium was introduced in 1949 as a treatment for mania, for which there is still the strongest evidence of its efficacy. It has consistently yielded better results in the treatment of mania than neuroleptics and carbamazepine and equivalent results to divalproex. Its efficacy in bipolar depression remains inadequately studied. Lithium also provides benefit in prophylaxis. However, the percentage of patients persistently benefited is low, because it has both low efficacy in many symptomatic and illness course presentations of the disorder and low tolerability. Converging evidence from clinical and animal studies indicates that a principal behavioral effect of lithium is reduction of motor activity. Lithium is increasingly used in combined treatment regimens, often thereby allowing lower, better tolerated dosing and complementary benefits from drugs with different profiles of action.

AB - Lithium was introduced in 1949 as a treatment for mania, for which there is still the strongest evidence of its efficacy. It has consistently yielded better results in the treatment of mania than neuroleptics and carbamazepine and equivalent results to divalproex. Its efficacy in bipolar depression remains inadequately studied. Lithium also provides benefit in prophylaxis. However, the percentage of patients persistently benefited is low, because it has both low efficacy in many symptomatic and illness course presentations of the disorder and low tolerability. Converging evidence from clinical and animal studies indicates that a principal behavioral effect of lithium is reduction of motor activity. Lithium is increasingly used in combined treatment regimens, often thereby allowing lower, better tolerated dosing and complementary benefits from drugs with different profiles of action.

UR - http://www.scopus.com/inward/record.url?scp=0033939121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033939121&partnerID=8YFLogxK

M3 - Article

C2 - 10826659

AN - SCOPUS:0033939121

VL - 61

SP - 35

EP - 40

JO - The Journal of clinical psychiatry

JF - The Journal of clinical psychiatry

SN - 0160-6689

IS - SUPPL. 9

ER -